Our Partners

BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and inter-ventional procedures, and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has nearly 50,000 associates across fifty countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.

Healthcare systems around the world are amazingly complex. For healthcare to improve, it must be more broadly accessible; delivered more safely, quickly, and effectively; and a more satisfying experience for everyone involved. At Microsoft, we’re focused on the heroes of healthcare, the people developing new, safer, and more effective therapies, the people who provide treatment, the patients who receive it, and the administrators who make everything run smoothly.

Our role is to assist these heroes and augment what they do with our expertise in cloud, business processes, enterprise productivity, and Artificial Intelligence. We want to make their lives—and through them, the lives of all individuals—better.

Through the power of technology, Cisco empowers healthcare organizations to deliver innovative patient care, streamline workflows for care teams, optimize clinical and business operations, and facilitate security and compliance. With 20 years of experience working with providers, payers, device manufacturers, and pharmaceutical companies, our leadership is unmatched around the world. We empower innovation at more than 17,000 healthcare organizations in 118 countries. Every day, we push the boundaries of what is possible in healthcare. Our commitment to forward-thinking healthcare lays the foundation for tomorrow.

We help healthcare organizations achieve their desired business outcomes with SaaS offers, such as conferencing solutions for employees or patients and healthcare-specific solutions—such as Cisco Patient Connect and Extended Care—for personalization and collaboration. Our comprehensive portfolio fits any work environment, from the patient’s bedside to the doctor’s home, from the administrative back office to the research laboratory. Cisco delivers collaboration through the cloud, on site, or through a hybrid combination of the two, with always-on solutions that enable high-quality interactions among patients and care teams, scalability across facilities and branches, and end-to-end security.

At SGInnovate, we build and scale Deep Tech startups into high potential companies with global impact. We believe that hard global problems can be solved using Deep Tech, and Singapore, where we are based, is uniquely positioned to realise Deep Tech innovations that can tackle these challenges. Our Deep Tech Nexus Strategy is focused on adding tangible value to the Deep Tech startup ecosystem in two key areas – development of Human Capital and deployment of Investment Capital. With the support of our partners and co-investors, we back entrepreneurial scientists through equity-based investments, access to talent and business-building advice. Our efforts are prioritised around emerging technologies such as Artificial Intelligence, Autonomous Tech, MedTech and Quantum Tech, which represent impactful and scalable answers to global challenges. SGInnovate is a private-limited company wholly owned by the Singapore Government. For more information, please visit www.sginnovate.com

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but also will help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

The Singapore Economic Development Board (EDB), a government agency under the Ministry of Trade and Industry, is responsible for strategies that enhance Singapore’s position as a global centre for business, innovation, and talent. We undertake investment promotion and industry development, and work with international businesses, both foreign and local, by providing information, connection to partners and access to government incentives for their investments. Our mission is to create sustainable economic growth, with vibrant business and good job opportunities for Singapore.

The Saw Swee Hock School of Public Health aims to continually foster healthier communities in Singapore and the region, and impact public health programmes and policies through its robust educational programmes and translational cross-disciplinary research work on cohort studies and life course epidemiology, infectious disease research, health technology assessments, health promotion, workplace safety and health, health systems evaluation and health services research. An interdisciplinary approach, augmented by rigorous training, applicable research and regional partnerships, places SSHSPH at the forefront of public health knowledge discovery and practice in Asia.

Founded in 2002, Ying is an integrated communications agency focused on helping clients bring their B2B stories to life in Asia. It was started with just two people who shared a love for the amazing innovations, exceptional engineering and industry-changing technology. Today, Ying is more than 40 strong in Singapore, delivering B2B marketing and B2B PR to some of the most innovative companies in the world. In 2017, it was acquired by New York-based Finn Partners, one of the fastest growing independent public relations agencies in the world. With more than 700 professionals, Finn Partners provides its clients with global access and capabilities through 18 offices across three continents. Finn Partners has an award-winning healthcare practice that works with some of the best-known names in the industry to help them convey value using skilled patient advocacy, traditional and digital media and policy support.

Anthill Ventures is a premier, global speed-scaling ecosystem for growth stage startups. Its unique ability is to source, invest, rapidly scale early-stage companies, subsequently enabling them to raise or syndicate funding within 12 to 18 months. Its dedicated team spread across Hyderabad, Mumbai, Bengaluru and Singapore enables the startups with an extensive global network of venture capitalists and investors, market access opportunities from corporates, and expertise from mentors and luminaries in the technology industry. Anthill Ventures primarily focuses on exciting technology startups in verticals such as healthtech, life sciences, media and entertainment, urbantech and smart cities.

Upjohn is a Pfizer division covering 20 iconic brands, operating with dedicated resources in more than 66 markets, 32 markets with direct commercial or medical presence and more than 34 alliance markets, and serving 54 million patients. Upjohn portfolio includes 20 industry-leading brands in the areas of cardiovascular disease, pain, urology, psychiatry, and other Non-Communicable Diseases (NCDs). Being a stand-alone division within Pfizer, Upjohn combines the agility of a start-up with the resources and capabilities of a Fortune 100 enterprise.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our portfolio of medicines for therapeutic areas include vaccines, oncology, cardiovascular diseases, infectious diseases, immunological disorders, rare diseases and mental health.

Research and development are the heart and soul of everything we do. As one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, government agencies and local communities to expand access to reliable and affordable health care.

FHI 360 is an international nonprofit working to improve the health and well-being of people in the United States and around the world.

We partner with governments, the private sector and civil society to bring about positive social change and to provide lifesaving health care, quality education and opportunities for meaningful economic participation. We do this by using research and evidence to design and deliver innovative programs that change behaviors, increase access to services and improve lives.

Our staff of more than 4,000 professionals work in more than 60 countries. Their diverse technical expertise and deep understanding of local conditions provide a 360-degree perspective that allows us to develop customized responses to the toughest human development challenges.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.

We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our portfolio of medicines for therapeutic areas include vaccines, oncology, cardiovascular diseases, infectious diseases, immunological disorders, rare diseases and mental health.

Research and development are the heart and soul of everything we do. As one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, government agencies and local communities to expand access to reliable and affordable health care.

FHI 360 is an international nonprofit working to improve the health and well-being of people in the United States and around the world.

We partner with governments, the private sector and civil society to bring about positive social change and to provide lifesaving health care, quality education and opportunities for meaningful economic participation. We do this by using research and evidence to design and deliver innovative programs that change behaviors, increase access to services and improve lives.

Our staff of more than 4,000 professionals work in more than 60 countries. Their diverse technical expertise and deep understanding of local conditions provide a 360-degree perspective that allows us to develop customized responses to the toughest human development challenges.